Quick Answer
BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Total Revenue of $17.8 thousand for fiscal year 2019.
BIOFORCE NANOSCIENCES HOLDINGS, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $17.8K +9.0% |
| Net Income | -$490.4K -3.9% |
-$472.0K +2.8% |
-$485.5K +3.3% |
-$502.0K +99.7% |
-$158.41M -340285.4% |
-$46.5K +31.3% |
| Diluted EPS | -$0.02 +0.0% |
-$0.02 +0.0% |
-$0.02 | — | — | — |
| Total Assets | $862.00 +35.1% |
$638.00 -13.1% |
$734.00 -93.4% |
$11.1K -72.0% |
$39.9K -32.3% |
$58.9K +67.7% |
| Cash and Equivalents | $862.00 +35.1% |
$638.00 -13.1% |
$734.00 -93.4% |
$11.1K -72.1% |
$39.9K -24.6% |
$52.9K +80.0% |
| Stockholders Equity | -$2.30M -26.5% |
-$1.82M -35.0% |
-$1.35M -56.3% |
-$861.9K -139.5% |
-$359.9K -860.8% |
$47.3K +58.7% |
| Operating Income | — | — | — | — | — | -$46.5K +30.3% |
| Gross Profit | — | — | — | — | — | $4.4K -6.5% |
| Shares Outstanding | 29.27M +0.0% |
29.27M +0.0% |
29.27M +0.0% |
29.27M +0.0% |
29.27M +91.7% |
15.27M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2019 | $6.0K | +8.2% | +0.0% |
| Net Income | September 30, 2025 | -$115.9K | +5.0% | +5.6% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $784.00 | -52.0% | -13.4% |
| Cash and Equivalents | September 30, 2025 | $784.00 | -52.0% | -13.4% |
| Stockholders Equity | September 30, 2025 | -$499.9K | +77.1% | -30.2% |
| Operating Income | September 30, 2025 | -$115.9K | +5.0% | +5.6% |
| Gross Profit | September 30, 2019 | $1.7K | +8.2% | +81.8% |
| Shares Outstanding | September 30, 2025 | 33.52M | +14.5% | +0.0% |
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Total Revenue of $17.8 thousand for fiscal year 2019.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed an increase of +9.0% in Total Revenue compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Net Income of -$490.4 thousand for fiscal year 2024.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed a decrease of -3.9% in Net Income compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2024.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Total Assets of $862.00 for fiscal year 2024.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed an increase of +35.1% in Total Assets compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Cash and Equivalents of $862.00 for fiscal year 2024.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed an increase of +35.1% in Cash and Equivalents compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Stockholders Equity of -$2.30 million for fiscal year 2024.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed a decrease of -26.5% in Stockholders Equity compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Operating Income of -$46.5 thousand for fiscal year 2019.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed an increase of +30.3% in Operating Income compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Gross Profit of $4.4 thousand for fiscal year 2019.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed a decrease of -6.5% in Gross Profit compared to the prior fiscal year.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. reported Shares Outstanding of 29.27 million shares for fiscal year 2024.
- BIOFORCE NANOSCIENCES HOLDINGS, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: